Genomictree Inc.
228760
Classement en actions
#19260
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Prix de l'action
$6.57
Capitalisation boursière
$161.24M
Changement (1 jour)
-0.63%
Changement (1 an)
-51.24%
Pays
KR
Échange Genomictree Inc. (228760)
Catégorie
Healthcare
Capitalisation boursière de Genomictree Inc.(228760)
Capitalisation boursière: $161.24M
En October 2026, Genomictree Inc. a une capitalisation boursière de $161.24M. Cela fait de Genomictree Inc. la 19260th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Genomictree Inc. du 2017 au 2026
228760 par rapport au top 5 des plus populaires stocks
